MedElevator Войти в исследования
← Поиск публикаций

DOI 10.2147/jhc.s600557

Медицинская библиотека · Journal of hepatocellular carcinoma · 2026

HAIC Combined with Lenvatinib and Pembrolizumab for Unresectable Hepatocellular Carcinoma: A Retrospective Study.

Liang Jun, Yang Zhenyun, Yang Zhuolin, Li Haozhong, Hong Jincheng, Pan Yangxun, Fu Yizhen, Wang Juncheng, Zhou Zhongguo, Zhang Yaojun, Chen Minshan, Chen Jinbin, Hu Dandan

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND & AIMS: The optimal treatment strategy for unresectable hepatocellular carcinoma (uHCC) remains under active investigation. Hepatic arterial infusion chemotherapy (HAIC) has shown promising outcomes, particularly among patients with high intrahepatic tumor burden. We assessed outcomes and tolerability of HAIC combined with lenvatinib and pembrolizumab (HAIC+L+P) as initial treatment for uHCC.

METHODS

We retrospectively identified consecutive, treatment-naïve patients with uHCC (BCLC stage B/C) treated with HAIC+L+P at a single center from January 2019 to January 2024. Tumor responses were evaluated using RECIST 1.1 and mRECIST. Overall survival (OS), progression-free survival (PFS), and treatment-related adverse events (AEs) were analyzed.

RESULTS

Sixty-six patients were analyzed, of whom 81.8% had BCLC stage C disease, 68.2% had vascular invasion, and 45.5% had extrahepatic metastasis. The median PFS was 9.63 months (95% CI, 6.59-12.68), and the median OS was 27.50 months (95% CI, 18.17-36.83). The ORR was 47.0% according to RECIST 1.1 and 66.7% according to mRECIST, with a DCR of 90.9% by both criteria. Six patients (9.1%) underwent curative-intent surgical resection during treatment. All AEs were controllable and no treatment-related deaths were recorded.

CONCLUSION

HAIC combined with lenvatinib and pembrolizumab was associated with encouraging antitumor activity and a manageable safety profile in this real-world cohort. These findings should be considered hypothesis-generating and warrant validation in prospective controlled studies.

Для цитирования: Liang Jun, Yang Zhenyun, Yang Zhuolin, Li Haozhong, Hong Jincheng, Pan Yangxun, Fu Yizhen, Wang Juncheng, Zhou Zhongguo, Zhang Yaojun, Chen Minshan, Chen Jinbin, Hu Dandan. HAIC Combined with Lenvatinib and Pembrolizumab for Unresectable Hepatocellular Carcinoma: A Retrospective Study.. Journal of hepatocellular carcinoma. 2026. DOI: 10.2147/jhc.s600557.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.